New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Safe, healthy and sustainable diets in the Netherlands: opportunities for integrated policy The Netherlands aims to take the lead in the international ambition for a healthy, sustainable and safe dietary pattern.
International Salmonella outbreak seems to have been resolved There has been an ongoing outbreak of Salmonella enteritidis in Europe since 2015. It has also been present in the Netherlands since May 2016.
Assessment of health effects of alternative tobacco products To assess the effects on the health of users of alternative tobacco products, more knowledge is required about the composition of the product, the smoker’s behaviour (such as the amount of cigarett
RIVM and German BfR enter cooperation agreement on animal protection and food safety The German Federal Institute of Risk Assessment (BfR) and the Dutch National Institute for Public Health and the Environment, RIVM have signed a cooperation agreement, focused on developing new sci
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
More tobacco products, number of additives stable In 2014, the number of tobacco products on the Dutch market increased to 4212. This is a 5 percent increase compared to 2013.
Breakthrough on cumulative risk assessment exposure to pesticides in food The European Commission, Member States and EFSA have taken a major step forward in their work on assessing the cumulative risks from exposure to pesticides in food.